Amarin Corp Plcuk (AMRN) Receivables - Net (2013 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Receivables - Net of $123.0 million for Q1 2026, up 3.68% YoY from $118.7 million in Q1 2025, and down 15.14% sequentially from $145.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Receivables - Net (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Receivables - Net across 14 years of filings, most recently posting $123.0 million for Q1 2026.
- In Q1 2026, Receivables - Net rose 3.68% year-over-year to $123.0 million; the TTM figure through Mar 2026 stood at $123.0 million (up 3.68% YoY), while the FY2025 annual figure was $145.0 million, up 8.95% from the prior year.
- Receivables - Net slipped to $123.0 million in Q1 2026, from $145.0 million in the prior quarter.
- Over the last five years, Receivables - Net for AMRN reached as high as $217.8 million in Q1 2022 and fell as low as $115.8 million in Q1 2024.
- The 5-year median for Receivables - Net is $131.0 million (2022), against an average of $141.0 million.
- The widest YoY moves for Receivables - Net: up 43.99% in 2022, down 46.16% in 2022.
- A 5-year view of Receivables - Net shows it stood at $131.0 million in 2022, then rose by 22.67% to $160.7 million in 2023, then fell by 17.19% to $133.1 million in 2024, then grew by 8.95% to $145.0 million in 2025, then dropped by 15.14% to $123.0 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $123.0 million, $145.0 million, and $127.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.04 Mn |
| Mar 31, 2026 | 123.04 Mn |
| Dec 31, 2025 | 144.98 Mn |
| Dec 31, 2025 | 144.98 Mn |
| Sep 30, 2025 | 127.30 Mn |
| Sep 30, 2025 | 127.30 Mn |
| Jun 30, 2025 | 119.13 Mn |
| Jun 30, 2025 | 119.13 Mn |
| Mar 31, 2025 | 106.70 Mn |
| Mar 31, 2025 | 106.70 Mn |
| Dec 31, 2024 | 133.07 Mn |
| Dec 31, 2024 | 133.07 Mn |
| Sep 30, 2024 | 130.25 Mn |
| Sep 30, 2024 | 130.25 Mn |
| Jun 30, 2024 | 150.63 Mn |
| Jun 30, 2024 | 150.63 Mn |
| Mar 31, 2024 | 115.81 Mn |
| Mar 31, 2024 | 115.81 Mn |
| Dec 31, 2023 | 160.69 Mn |
| Dec 31, 2023 | 160.69 Mn |